Supernus Pharmaceuticals (NASDAQ: SUPN) CMO receives 750 performance share units

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. reported that SVP and Chief Medical Officer Jonathan Rubin acquired 750 Performance Share Units on July 29, 2026. These units are a portion of an award granted on February 19, 2025 that vested upon achievement of individual performance objectives established on May 3, 2025 and are tied to 750 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rubin Jonathan

Role SVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Performance Share Unit F1	750	$0.00	$0.00

Holdings After Transaction: Performance Share Unit — 750 shares (Direct)

Footnotes (1)

1. F1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Key Figures

Performance Share Units acquired: 750 Performance Share Units Underlying common shares: 750 shares of Common Stock Transaction price per unit: $0.0000 per unit +2 more

5 metrics

Performance Share Units acquired 750 Performance Share Units Derivative award to Jonathan Rubin on July 29, 2026

Underlying common shares 750 shares of Common Stock Shares underlying the reported Performance Share Units

Transaction price per unit $0.0000 per unit Grant/award acquisition price for the Performance Share Units

Original award date February 19, 2025 Date the Performance Share Units were initially awarded

Performance objectives set May 3, 2025 Date individual performance objectives for vesting were established

Key Terms

Performance Share Unit, individual performance objectives, defined performance period

3 terms

Performance Share Unit financial

"the Reporting Person was awarded Performance Share Units, a portion of which vested"

A performance share unit (PSU) is a form of executive or employee pay that promises shares (or the cash value of shares) only if the company meets specific performance targets over a set period. Think of it like a bonus cheque that only arrives if the company hits agreed goals — it aligns managers’ rewards with business results and signals to investors how leadership is being incentivized to grow value over time.

individual performance objectives financial

"vested upon the achievement of individual performance objectives within a defined performance period"

defined performance period financial

"achievement of individual performance objectives within a defined performance period"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/31/2026 - 05:04 PM Accepted by SEC EDGAR 07/31/2026 - 05:04 PM Learn about SEC filing dates

FAQ

What insider transaction did SUPN report for Jonathan Rubin on July 29, 2026?

Jonathan Rubin reported acquiring 750 Performance Share Units on July 29, 2026. These derivative awards are tied to an equal number of shares of common stock and stem from a prior 2025 performance-based grant.

How many shares are underlying the 750 Performance Share Units reported at SUPN?

The 750 Performance Share Units correspond to 750 shares of Common Stock. Each unit represents a right linked to one share, reflecting equity-based compensation rather than an open-market stock purchase or sale.

When were Jonathan Rubin’s Performance Share Units at SUPN originally awarded and how do they vest?

The Performance Share Units were awarded on February 19, 2025. A portion vested upon achieving individual performance objectives within a defined performance period, with those objectives established on May 3, 2025, linking vesting directly to personal performance criteria.

What is Jonathan Rubin’s position at SUPERNUS PHARMACEUTICALS (SUPN)?

Jonathan Rubin serves as SVP, Chief Medical Officer at SUPERNUS PHARMACEUTICALS, INC. His Form 4 filing reflects equity-based compensation tied to this executive role, reported as a direct ownership position in derivative securities.

Was Jonathan Rubin’s SUPN Performance Share Unit transaction under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as an affirmatively adopted trading plan. The reported acquisition reflects performance-based equity vesting rather than trades executed under a pre-arranged Rule 10b5-1 sales or purchase program.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubin Jonathan

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	$0	07/29/2026		A		750		(1)	(1)	Common Stock	750	$0	750	D

Explanation of Responses:

1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)